Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

30
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
30
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

21
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
21
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

49
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
49

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adjuvant Chemotherapy ± Chemoradiotherapy for Adenocarcinoma of the Pancreatic Head: Results of the Radiotherapy Random Assignment of NRG Oncology/RTOG 0848.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Thrombocytopenia in Pregnancy: A 5-Year Analysis of Characteristics and Practices From a Tertiary Academic Center.

International journal of laboratory hematology·2026
Same author

Understanding Patient Perspectives on Radiation Tattoos.

Advances in radiation oncology·2026
Same author

A 70-year-old man with lower-extremity weakness and falls.

Cleveland Clinic journal of medicine·2026
Same author

Clinical presentation and treatment of a case of anti-signal recognition particle-positive immune-mediated necrotizing myopathy.

Proceedings (Baylor University. Medical Center)·2026
Same author

Antiphospholipid syndrome (APS) is a platelet factor 4 (PF4)-centric immunothrombotic disorder.

Blood·2026

Related Experiment Video

Updated: Sep 5, 2025

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.5K

Race, rituximab, and relapse in TTP.

Shruti Chaturvedi1, Ana G Antun2, Andrew M Farland3

  • 1Department of Medicine, Johns Hopkins University, Baltimore, MD.

Blood
|July 7, 2022
PubMed
Summary

Black patients with immune-mediated thrombotic thrombocytopenic purpura (iTTP) experience shorter relapse-free survival and a different response to rituximab therapy compared to White patients. Further research into social determinants of health is needed to address these disparities.

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

252
Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
09:54

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

3.6K

Related Experiment Videos

Last Updated: Sep 5, 2025

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.5K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

252
Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
09:54

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

3.6K

Area of Science:

  • Hematology
  • Immunology
  • Health Disparities

Background:

  • Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a serious condition causing organ damage due to blood clots.
  • Black patients are disproportionately affected by iTTP in the U.S., but racial differences in outcomes and treatment response are not well understood.

Purpose of the Study:

  • To investigate the impact of race on mortality and relapse-free survival (RFS) in patients with iTTP.
  • To examine how race influences the effectiveness of rituximab therapy in both newly diagnosed and relapsed iTTP cases.

Main Methods:

  • Analysis of data from the United States Thrombotic Microangiopathies Consortium iTTP Registry (1995-2020).
  • Evaluation of 1308 iTTP episodes in 645 participants, comparing outcomes based on race.
  • Stratified analysis of rituximab treatment impact on RFS by race and disease status (de novo vs. relapsed).

Main Results:

  • No significant difference in acute iTTP mortality between racial groups.
  • Black patients had significantly shorter RFS compared to White patients across all iTTP episodes.
  • Rituximab improved RFS in White patients but not in Black patients, particularly in relapsed iTTP.

Conclusions:

  • Race significantly impacts iTTP relapse risk and response to rituximab.
  • Black patients may necessitate closer monitoring, earlier interventions, and alternative immunosuppressive strategies post-rituximab.
  • Further investigation into the roles of racism and social determinants of health in iTTP disparities is warranted.